• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23151 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     National Institute for Health and Care Excellence (NICE) Maximal cytoreductive surgery for advanced ovarian cancer. NICE interventional procedures guidance 757
2023     National Institute for Health and Care Excellence (NICE) Focal therapy using high-intensity focused ultrasound for localised prostate cancer. NICE interventional procedures guidance 756
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thoracic duct embolisation for persistent chyle leak. NICE interventional procedures guidance 755
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. NICE interventional procedures guidance 759
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided biliary drainage for biliary obstruction. NICE interventional procedures guidance 761
2023     National Institute for Health and Care Excellence (NICE) Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea. NICE interventional procedures guidance 760
2023     National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. NICE interventional procedures guidance 762
2023     National Institute for Health and Care Excellence (NICE) Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. NICE interventional procedures guidance 763
2023     National Institute for Health and Care Excellence (NICE) Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766
2023     National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating prostate cancer. NICE interventional procedures guidance 768
2023     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. NICE interventional procedures guidance 769
2023     National Institute for Health and Care Excellence (NICE) Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023     National Institute for Health and Care Excellence (NICE) Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023     National Institute for Health and Care Excellence (NICE) Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023     National Institute for Health and Care Excellence (NICE) Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2023     National Institute for Health and Care Excellence (NICE) Extracorporeal carbon dioxide removal for acute respiratory failure. NICE interventional procedures guidance 776
2023     National Institute for Health and Care Excellence (NICE) Biodegradable subacromial spacer insertion for rotator cuff tears. NICE interventional procedures guidance 775
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023     National Institute for Health and Care Excellence (NICE) Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023     The Danish Health Technology Council (DHTC) [Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A21-131]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burnout: Can yoga help cope?]
2023     Haute Autorite de sante (HAS) [2023 update: clinical utility of genomic signatures in early-stage HR-positive/HER2-negative breast cancer]
2023     Haute Autorite de sante (HAS) [Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2023     Haute Autorite de sante (HAS) [Assessment of the exhaled nitric oxide measurement for asthma management]
2023     The Danish Health Technology Council (DHTC) [Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness and safety of newborn screening for spinal muscular atrophy. Systematic review]
2023     The Danish Health Technology Council (DHTC) [Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Contraception: comparison of hormonal coils and copper coils]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023     National Institute for Health and Care Excellence (NICE) Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023     National Institute for Health and Care Excellence (NICE) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of clazosentan (Pivlaz)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) (Cost-effectiveness evaluation of Valbenazine (Dysval) for tardive dyskinesia)
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Efgartigimod Alfa (Vyvgart)]
2023     HTA Region Stockholm [Effects of nonsteroidal anti-inflammatory drugs (NSAID) on risk of exacerbation of disease in patients with inflammatory bowel disease (IBD)]
2023     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2023     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2023     National Institute for Health and Care Excellence (NICE) Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2023     National Institute for Health and Care Excellence (NICE) Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2023     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931
2023     National Institute for Health and Care Excellence (NICE) Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. NICE technology appraisal guidance 930
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 929
2023     National Institute for Health and Care Excellence (NICE) Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine. NICE technology appraisal guidance 928
2023     National Institute for Health and Care Excellence (NICE) Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 927
2023     National Institute for Health and Care Excellence (NICE) Baricitinib for treating severe alopecia areata. NICE technology appraisal guidance 926
2023     National Institute for Health and Care Excellence (NICE) Mirikizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 925
2023     National Institute for Health and Care Excellence (NICE) Tirzepatide for treating type 2 diabetes. NICE technology appraisal guidance 924
2023     National Institute for Health and Care Excellence (NICE) Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal). NICE technology appraisal guidance 923
2023     National Institute for Health and Care Excellence (NICE) Daridorexant for treating long-term insomnia. NICE technology appraisal guidance 922
2023     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating polycythaemia vera. NICE technology appraisal guidance 921
2023     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 920
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for treating migraine. NICE technology appraisal guidance 919
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 918
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 917
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating active psoriatic arthritis. NICE technology appraisal guidance 916
2023     National Institute for Health and Care Excellence (NICE) Pegunigalsidase alfa for treating Fabry disease. NICE technology appraisal guidance 915
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2023     National Institute for Health and Care Excellence (NICE) Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy. NICE technology appraisal guidance 913
2023     National Institute for Health and Care Excellence (NICE) Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912
2023     National Institute for Health and Care Excellence (NICE) Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 911
2023     National Institute for Health and Care Excellence (NICE) Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 910
2023     National Institute for Health and Care Excellence (NICE) Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 909
2023     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy. NICE technology appraisal guidance 908
2023     National Institute for Health and Care Excellence (NICE) Deucravacitinib for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 907
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for preventing migraine. NICE technology appraisal guidance 906
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 905
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 904
2023     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 903
2023     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 902
2023     National Institute for Health and Care Excellence (NICE) Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal). NICE technology appraisal guidance 901
2023     National Institute for Health and Care Excellence (NICE) Tixagevimab plus cilgavimab for preventing COVID-19. NICE technology appraisal guidance 900
2023     National Institute for Health and Care Excellence (NICE) Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal). NICE technology appraisal guidance 899
2023     National Institute for Health and Care Excellence (NICE) Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 898
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 897
2023     National Institute for Health and Care Excellence (NICE) Bulevirtide for treating chronic hepatitis D. NICE technology appraisal guidance 896
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. NICE technology appraisal guidance 895
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 894
2023     National Institute for Health and Care Excellence (NICE) Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. NICE technology appraisal guidance 893
2023     National Institute for Health and Care Excellence (NICE) Mosunetuzumab for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 892
2023     National Institute for Health and Care Excellence (NICE) Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 891
2023     National Institute for Health and Care Excellence (NICE) Difelikefalin for treating pruritus in people having haemodialysis. NICE technology appraisal guidance 890
2023     National Institute for Health and Care Excellence (NICE) Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023     National Institute for Health and Care Excellence (NICE) Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2023     National Institute for Health and Care Excellence (NICE) Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 887
2023     National Institute for Health and Care Excellence (NICE) Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. NICE technology appraisal guidance 886